MRK240802C103000
- 0.00
- 0.000.00%
Merck & Co Newsroom
UBS Maintains Buy on Merck & Co, Lowers Price Target to $142
Merck & Co Analyst Ratings
Analyzing Merck & Co In Comparison To Competitors In Pharmaceuticals Industry
Morgan Stanley Maintains Merck & Co(MRK.US) With Hold Rating, Cuts Target Price to $130
Evercore Maintains Merck & Co(MRK.US) With Buy Rating
BofA Securities Initiates Merck & Co(MRK.US) With Buy Rating
A Quick Look at Today's Ratings for Merck & Co(MRK.US), With a Forecast Between $125 to $150
Merck & Company (MRK) Gets a Hold From Morgan Stanley
Buy Rating on Merck & Co. Amid Temporary Setbacks and Strong Growth Outlook
Express News | Merck & Co Inc : BofA Global Research Cuts Price Objective to $145 From $150
Wells Fargo Adjusts Price Target on Merck & Co. to $125 From $140, Maintains Equalweight Rating
Pertussis Treatment Market Projected to Hit US$ 5.3 Billion by 2034, With a 3.4% CAGR | Fact.MR Report
Express News | Merck & Co., Inc. : Morgan Stanley Cuts Target Price to $130.00 From $134.00
Express News | Merck & Co Inc : Guggenheim Cuts Target Price to $138 From $142
Nasdaq Tumbles Amid Decline In Tech Stocks: Greed Index Moves To 'Fear' Zone
Fat loss and muscle building, the flexibility "combination punch" of Kai Medical (2105.HK) is worth paying attention to.
Summary: In the race to build muscle and reduce fat, Eli Lilly and Co's bimagrumab is leading the clinical trials and its phase 2b clinical trial results may be announced soon; Lai Kai Pharmaceuticals' flexible "combination punch" is worth paying attention to - through flexible combinations, it may be possible to achieve better efficacy and safety ratios. Sarcopenia, or muscle loss, is a typical degenerative disease in the elderly. In today's pharmaceutical industry, research and development of drugs to slow down muscle loss or enhance muscle strength is a hot topic, and in the field of obesity, reducing fat and building muscle is also becoming the focus of many pharmaceutical companies. Since semaglutide,
Top 20 US stock turnover on July 30: CrowdStrike was sued by Delta Air Lines for a second time, causing its stock price to fall again.
On Tuesday, Nvidia, the number one trading volume stock in US stocks, fell by 7.04% with a turnover of 49.34 billion US dollars. According to TrendForce's latest AI Server report, Nvidia will launch a new generation platform called Blackwell before the end of 2024. By then, large CSP (cloud service providers) will also begin building Blackwell's new platform AI Server datacenter, estimated to have a chance to raise the penetration rate of liquid cooling schemes to 10%. A research paper released by Apple on Monday showed that Apple relies on Google, not the industry leader Nvidia.
Equity Markets Close Mixed Ahead of Fed Decision
Merck & Co Options Spot-On: On July 30th, 152.09K Contracts Were Traded, With 340.61K Open Interest
Sector Update: Health Care Stocks Edge Higher Late Afternoon